Impel Pharmaceuticals is focused on developing and providing transformative therapies for people suffering from diseases with high unmet needs across various disease areas in addition to the central nervous system (CNS), through the pioneering of an optimized approach to drug delivery. We offer and develop treatments that pair the Company’s proprietary Precision Olfactory Delivery (POD®) technology with well-established therapeutics. 

Impel Pharmaceuticals

Summer is a tough time of year for #migraine and #headaches. To best celebrate #freedom with your friends and family, be mindful of your triggers and keep your acute meds on hand.
 
Wishing everyone a safe and happy #IndependenceDay!

Trudhesa® (DHE mesylate) delivers a trusted #migraine therapeutic to the vascular-rich upper nasal space via the POD® device developed by our co-founder, CTO & CDO, John Hoekman. This results in IV-like efficacy at home - not via injection in an ER.

The Impel team proudly supports the #migraine community. Today we're wearing our #ShadesForMigraine to raise awareness about this complex, neurological disease that's more than just a #headache. 

#MHAM #MigraineAwareness

A second poster on preliminary real-world data underscores the need for non-oral treatment options for #migraine given the prevalence of pre-existing #gastrointestinal disorders among those prescribed with Trudhesa® (DHE mesylate).

See abstract P-160 in Headache: https://lnkd.in/eV8n_mNw

Read our press release to learn more: https://lnkd.in/eEkwReSh

#MHAM Dr. Sheena Aurora

Preliminary real-world data at #AHSAM suggest that concomitant preventive & acute medication use generally decreases in patients taking Trudhesa® (DHE mesylate) nasal spray, and that use of antinausea medications (common with DHE administered via IV) did not increase.

See abstract P-161 in Headache: https://lnkd.in/eV8n_mNw

Read yesterday's press release to learn more: https://lnkd.in/eEkwReSh 

#Migraine #MHAM Zubair Ahmed

Domain Not Resolving

DNSSEC

Microsoft Exchange Online

DMARC

Office 365 Mail

Person Schema

Google

Google Cloud

Gravatar Profiles

Chief Commercial Officer (CCO)

Mr. Leonard Paolillo

Vice President, Marketing

Jennifer Berman

Sr Vice President Regulatory Affairs, Impel Pharmaceuticals Inc.

Lynn Gold

VP, Quality

Mike Malafronte

SVP Technical Operations

Scott Youmans

Vice President Medical Affairs

Sheena Aurora

Senior Director Regulatory Affairs

Beatrix Taylor

Senior Director, Financial Planning & Analysis

Chris Jeffries

Senior Director of Technical Operations, Devices

Christopher Fuller

Director Drug Development & Manufacturing

Greg Davies

Aaron Royston

James W. Young

Jon Congleton

Robert Mittendorff

Mahendra G. Shah

Timothy S. Nelson

Ali Satvat

John Hoekman

Co-Founder, Chief Scientific Officer, Chief Technology, and Development Officer

VP of Medical Affairs – Migraine

John Leaman

Senior Vice President, Technical Operations

Michael Malafronte

VP of Quality

Ellen Lubman

Chief Business Officer

Senior VP of Regulatory

Meghan Swardstrom

VP of Clinical Development Operations

Pharmaceutical Public Companies With More Than 10 Employees

Pharmaceutical Companies With Fewer Than 100 Employees (Top 10K)

Greater Seattle Area Biotechnology Companies

Western US Biotechnology Companies

Impel Pharmaceuticals is a late-stage pharmaceutical company focused on utilizing its proprietary technology to develop and commercialize transformative therapies for people suffering from diseases with high unmet needs, with an initial focus on diseases of the CNS. The Company’s strategy is to rapidly advance its product candidate pipeline that pairs its proprietary Precision Olfactory Delivery (POD) system with well-established therapeutics, including TRUDHESA™ for the acute treatment of migraine, INP105 for the acute treatment of agitation and aggression in patients with autism, and INP107 for OFF episodes in Parkinson’s disease.

Oaktree Capital Management

Post-IPO Debt - Impel Pharmaceuticals

Post-IPO Equity - Impel Pharmaceuticals

Oxford Finance LLC

Silicon Valley Bank

Debt Financing - Impel Pharmaceuticals

Kohlberg Kravis Roberts

Norwest Venture Partners

Series D - Impel Pharmaceuticals

Series C - Impel Pharmaceuticals

3M New Ventures

Series B - Impel Pharmaceuticals

Alliance of Angels

Venture Round - Impel Pharmaceuticals

Seattle

Washington

United States

North America

Pharma Co. Impel's Ch. 11 Liquidation Plan Approved

Impel Pharmaceuticals completes sale to investors after bankruptcy filing

Impel Pharmaceuticals completes sale to investors after bankruptcy filing - Puget Sound Business Journal

Bankrupt Pharma Co. Impel Gets OK For $17.5M Sale

Cytovation Announces Appointment of Ellen Lubman, MBA to ...

Impel Pharmaceuticals Inc.(NasdaqGM:IMPL) dropped from S&P TMI Index

A nasal spray containing dihydroergotamine mesylate for the acute treatment of migraine with or without aura in adults.

A proprietary drug delivery system designed to target the vascular-rich upper nasal space for rapid and consistent drug absorption.

A drug delivery system designed to target the vascular-rich upper nasal space for rapid absorption and consistent bioavailability.

Engagements with other entities to explore the therapeutic potential of Impel's technology and expertise with both small and large molecules.

Opportunities for partnerships, collaborations, and licensing to explore the therapeutic potential of Impel's technology with both small and large molecules.

Philippines

Asia

HTML5

Google Fonts

Wordpress

Microsoft Outlook

GoDaddy Premium DNS

Google Analytics

Impel Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is Trudhesa, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. The company is also developing INP105, an upper nasal formulation of olanzapine for the acute treatment of agitation and aggression in autism spectrum disorder; and INP107, an upper nasal formulation of carbidopa/levodopa, which has completed Phase IIa clinical trial for the treatment of OFF episodes in Parkinson's disease. Impel Pharmaceuticals Inc. was formerly known as Impel NeuroPharma, Inc. and changed its name to Impel Pharmaceuticals Inc. in April 2022. Impel Pharmaceuticals Inc. was incorporated in 2008 and is headquartered in Seattle, Washington.

news impact assignment basic	general
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general	Dec 4, 2024 8:54 AM	4504575f
crunchbase profile	general	Dec 4, 2024 12:45 PM	231b0f7c
li profile	general	Feb 1, 2024 10:46 PM	0b0e1ae8
translate crunchbase fundingrounds	general	Dec 4, 2024 1:38 PM	32694586
peers	general	Feb 1, 2024 10:46 PM	5ee9ef8d
news basic	general
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:IMPELPHARMA

Impel Pharmaceuticals Inc.

Last Close

0.06

20/12 20:58

Market Cap

956K

Beta: -

Volume Today

720.03K

Avg: -